Tuesday, Aug. 10, 2021 : Issue #1157 |
|
Letter from the Editor
 Luseogliflozin is an SGLT-2 inhibitor that has been available since 2014 in Japan, but has never been released in the US. Based on a study that our intern, Torré Anderson, II, Fourth Year Doctor of Pharmacy Candidate, Florida A&M University College of Pharmacy, has for us this week, it may be possible that the company is thinking about making a US entrance.
His feature looks at how changing from a DPP4-I to this SGLT-2 inhibitor can make a big difference in hypertension and related heart problems. Take a look at his article and make a choice as to whether you think the effects are limited to this medication or class wide.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
